The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 trial of the PARP inhibitor fuzuloparib in combination with the anti-angiogenic apatinib in recurrent ovarian or triple-negative breast cancer.
 
Huiping Li
No Relationships to Disclose
 
Jiayang Zhang
No Relationships to Disclose
 
Rutie Yin
No Relationships to Disclose
 
Nan Song
No Relationships to Disclose
 
Youzhong Zhang
No Relationships to Disclose
 
Yu Zhang
No Relationships to Disclose
 
Keqiang Zhang
No Relationships to Disclose
 
Hongming Pan
No Relationships to Disclose
 
Ke Wang
No Relationships to Disclose
 
Ge Lou
No Relationships to Disclose
 
Li Guiling
No Relationships to Disclose
 
Ben Zhang
Employment - Jiangsu Hengrui Pharmaceuticals Co, Ltd.
 
Quanren Wang
Employment - Jiangsu Hengrui Pharmaceuticals
Stock and Other Ownership Interests - Jiangsu Hengrui Pharmaceuticals
 
Yunong Gao
No Relationships to Disclose